Site-Specific PEGylation of IGF-I via IgA Protease Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for PEGylation of proteins, such as insulin-like growth factor-I (IGF-I), often result in non-specific attachment to lysine residues, leading to reduced biological activity and unsuitable products due to inactivation of critical sites for receptor binding and enzymatic activity.
Innovation Solution
A method involving the production of lysine-PEGylated IGF-I variants by cultivating a prokaryotic host cell with an expression vector encoding a fusion protein N-terminally linked to a propeptide, followed by PEGylation and specific cleavage with IgA protease to achieve targeted PEGylation, ensuring attachment to specific lysine residues without affecting biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If PEGylation is performed on IGF-I using conventional methods, then the circulating half-life is extended, but the biological activity is reduced due to non-specific attachment to lysine residues
Solution Approach 1:
The patent applies local quality by introducing a specific lysine residue (K6 or K7) in the propeptide region that serves as a dedicated PEGylation site. This localized modification approach ensures that PEG attachment occurs at a predetermined position away from the biologically active region of IGF-I, thereby extending circulating half-life while preserving receptor binding activity and enzymatic function.
2Stability of the object's composition
If PEGylation is performed on all lysine residues, then the protein stability is improved, but the receptor binding activity is inactivated
Solution Approach 1:
The patent extracts the PEGylation function from the entire protein and relocates it to a specific location in the propeptide region. By creating a dedicated PEGylation site at lysine 6 or 7 of the propeptide, the method separates the stability-enhancing function of PEGylation from the activity-critical regions of IGF-I, allowing protein stability improvement without compromising receptor binding activity.
3Quantity of substance
If IGF-I is administered to treat Alzheimer's disease, then Aβ peptide levels are reduced, but the blood-brain barrier transport is insufficient due to large molecular size
Solution Approach 1:
The patent applies parameter changes by using site-specific PEGylation at the propeptide region, which creates a more favorable molecular configuration for blood-brain barrier penetration. The controlled modification at specific lysine residues (K6 or K7) alters the molecular parameters of IGF-I in a way that maintains its ability to cross the blood-brain barrier while preserving its Aβ-lowering efficacy in the brain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in IGF-I variants with improved stability and bioavailability, maintaining receptor activation and blood-brain barrier transport, effectively lowering Aβ peptide levels in the brain, thus offering a potential treatment for Alzheimer's disease.
Implementation Method 1
cleaving said PEGylated fusion protein with IgA protease wherein said IgA protease has the sequence SEQ ID NO:26
Implementation Method 2
conjugates of insulin-like growth factor-I and poly(ethylene glycol)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Method for the production of a lysine-PEGylated IGF-I or IGF-I variant, said variant comprising one or two amino acid(s) selected from the group consisting of lysine 27, 65 and/or 68 substituted independently by another polar amino acid, characterized in cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I or IGF-I variant N-terminally linked to the C-terminus of a propeptide, that said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering said PEGylated IGF-I or IGF-I variant. The PEGylated IGF-I or IGF-I variant is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.